Physician profile
Tamara Gurevich
NPI 1336227503
$4,324.17
in general payments reported to CMS, 2019-2025
31 companies · $663 in 2025
The $663 reported for 2025 was more than what 83% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $454 · 2021: $828 · 2022: $662 · 2023: $230 · 2024: $690 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,094.14 | 2019-2025 | |
| Amgen INC. | $385.00 | 2019-2025 | Otezla, Enbrel, Otezla |
| Ibsa Pharma INC. | $337.01 | 2020-2025 | Tirosint, Licart, Tirosint |
| Horizon Therapeutics Plc | $255.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $214.15 | 2019-2022 | |
| Abbott Laboratories | $110.24 | 2021-2023 | Proclaim |
| Janssen Biotech, INC. | $106.34 | 2019-2022 | |
| Biotronik Nro, INC. | $102.86 | 2024 | Prospera |
| Ucb, INC. | $88.69 | 2020-2022 | |
| Allergan, INC. | $68.68 | 2019-2021 | |
| Fidia Pharma USA INC. | $52.62 | 2021-2024 | Hyalgan, Hymovis, Triluron |
| Mallinckrodt Hospital Products INC. | $47.78 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $41.86 | 2024 | Spravato |
| Biodelivery Sciences International, INC. | $37.80 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $35.66 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $30.12 | 2022-2023 | Belbuca |
| Kowa Pharmaceuticals America, INC. | $27.61 | 2023 | Seglentis |
| Pfizer INC. | $26.47 | 2019 | |
| Genzyme Corporation | $25.00 | 2019 | |
| Si-Bone, INC. | $23.60 | 2021 | |
| Celgene Corporation | $23.02 | 2019 | |
| Boston Scientific Corporation | $22.97 | 2020 | |
| Mallinckrodt Enterprises LLC | $21.94 | 2019 | |
| Daiichi Sankyo INC. | $21.24 | 2019 | |
| Lilly USA, LLC | $21.07 | 2025 | Mounjaro, Zepbound |
| Orthogenrx INC. | $19.45 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.05 | 2022 | |
| Relievant Medsystems, INC. | $18.98 | 2022 | |
| Lundbeck LLC | $16.76 | 2024 | Vyepti |
| Assertio Therapeutics, INC. | $14.51 | 2019 | |
| Bioventus LLC | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Gurevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.